Steve Favaloro

Steve Favaloro is a passionate life sciences investor and entrepreneur. He is currently President and CEO of Genezen, a leading viral vector CDMO. Prior, Steve was CFO at Arbor Biotechnologies, a next generation gene editing therapeutic company. Steve also served as CFO at Arranta Bio, a leading CDMO for mRNA, from its founding in 2019 to its successful exit to Recipharm in February 2022. Prior to this, Steve was CFO at Brammer Bio, where he oversaw a period of rapid expansion and capital deployment from 2016 to 2019 – leading up to its successful sale to Thermo Fisher Scientific in May 2019 for $1.7B. Prior to joining Brammer, Steve held finance roles of increasing responsibility at MilliporeSigma, Merck KGaA, and Bruker Corporation. He received his MBA and Master of Science from the Carroll School of Management at Boston College. Steve also received his Bachelor of Arts degree in Economics from Boston College.

Why Genezen? I am inspired by the passion and devotion of my colleagues at Genezen everyday – our technical aptitude and ability to partner with customers is second to none.

I’m passionate about Our industry – we will fundamentally change the paradigm of medicine to tailored, curative therapies for patients.